2017 Annual Meeting | C12 - Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
| 10:30 AM - 10:35 AM | Luncheon |
Introduction
Laura M. Tormoehlen, MD, FAAN |
| 10:35 AM - 11:25 AM | Speaker |
What's in the Diagnosis: Seropositive, MuSK, and Seronegative Myasthenia Gravis
Janice M. Massey, MD, FAAN |
| 11:25 AM - 12:15 PM | Speaker |
Treatment of Autoimmune Myasthenia Gravis: Evidence-based and New Developments
Jeff Guptill, MD, FAAN |
| 12:15 PM - 12:30 PM | Q&A |
Questions and Answers
|
| Janice M. Massey, MD, FAAN | Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance . |
| Laura M. Tormoehlen, MD, FAAN | The institution of Dr. Tormoehlen has received research support from Genentech. Dr. Tormoehlen has received publishing royalties from a publication relating to health care. |
| Jeff Guptill, MD, FAAN | Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx. |